Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics
Liquidia Technologies, Inc. (LQDA)
Today's Latest Price: $2.90 USD
Updated Dec 4 4:00pm
Add LQDA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
LQDA Stock Summary
- Liquidia Technologies Inc's stock had its IPO on July 26, 2018, making it an older stock than only 4.6% of US equities in our set.
- With a price/sales ratio of 20.77, Liquidia Technologies Inc has a higher such ratio than 92.55% of stocks in our set.
- As for revenue growth, note that LQDA's revenue has grown 353.23% over the past 12 months; that beats the revenue growth of 98.08% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Liquidia Technologies Inc, a group of peers worth examining would be ETTX, EVGN, UMRX, NOVN, and SYBX.
- LQDA's SEC filings can be seen here. And to visit Liquidia Technologies Inc's official web site, go to www.liquidia.com.
LQDA Stock Price Chart Interactive Chart >
LQDA Price/Volume Stats
| Current price | $2.90 | 52-week high | $12.10 |
| Prev. close | $2.92 | 52-week low | $2.65 |
| Day low | $2.85 | Volume | 946,700 |
| Day high | $3.00 | Avg. volume | 452,063 |
| 50-day MA | $4.04 | Dividend yield | N/A |
| 200-day MA | $5.72 | Market Cap | 109.48M |
Liquidia Technologies, Inc. (LQDA) Company Bio
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.
Loading social stream, please wait...